DRRX DURECT Corporation

1.85
+0.05  (+3%)
Previous Close 1.8
Open 1.79
Price To Book 15.42
Market Cap 355,093,133
Shares 191,942,234
Volume 359,870
Short Ratio
Av. Daily Volume 952,292
Stock charts supplied by TradingView

NewsSee all news

  1. DURECT Announces Completion of Enrollment in its Phase 2a Clinical Trial of DUR-928 in Psoriasis and 50% Enrollment in its Phase 1b DUR-928 Clinical Trial in NASH

    CUPERTINO, Calif., Oct. 7, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that it has completed enrollment in its Phase 2a clinical trial of topical DUR-928 in patients with mild to moderate plaque

  2. DURECT Announces FDA Advisory Committee Meeting to Review POSIMIR® for the Treatment of Post-Surgical Pain

    CUPERTINO, Calif., Oct. 2, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that the U.S. Food and Drug Administration (FDA) has notified the Company that its Class 2 NDA resubmission for POSIMIR®

  3. DURECT to Present at the 2019 Cantor Fitzgerald Global Health Care Conference

    CUPERTINO, Calif., Sept. 26, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that James E. Brown, Chief Executive Officer will be presenting at the Cantor Fitzgerald Global Health Care Conference,

  4. DURECT Announces Positive Data from its Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis

    CUPERTINO, Calif., Sept. 17, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that it has completed the Phase 2a clinical trial of its lead product candidate, DUR-928, in patients with alcoholic

  5. DURECT Earns $10 Million Milestone Payment for Further Development of a Long-Acting Injectable HIV Investigational Product Utilizing DURECT's SABER® Technology

    CUPERTINO, Calif., Sept. 9, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that further development of a long-acting injectable HIV investigational product utilizing DURECT's SABER® technology

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA Approval announced July 27, 2018.
RBP-7000
Schizophrenia
Phase 2 top-line data due 4Q 2019.
DUR-928
Psoriasis
CRL issued February 12, 2014.
Posidur
Post-operative pain relief
CRL Feb 12 2014. New PDUFA date December 27, 2019. Advisory Committee meeting scheduled for January 16, 2020 will result in PDUFA date extension.
POSIMIR
Post-operative pain relief
Phase 3 to be initiated by ZGNX once partner is found.
Relday
Schizophrenia
Phase 1b trial to be completed 1H 2020 with data due following completion of trial.
DUR-928
Nonalcoholic steatohepatitis (NASH)
Phase 2 data noted statistically significantly greater reductions from baseline in bilirubin (day 7 and 28) and MELD compared with historical group - September 17, 2019.
DUR-928
Alcoholic hepatitis (AH)

Latest News

  1. DURECT Announces Completion of Enrollment in its Phase 2a Clinical Trial of DUR-928 in Psoriasis and 50% Enrollment in its Phase 1b DUR-928 Clinical Trial in NASH

    CUPERTINO, Calif., Oct. 7, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that it has completed enrollment in its Phase 2a clinical trial of topical DUR-928 in patients with mild to moderate plaque

  2. DURECT Announces FDA Advisory Committee Meeting to Review POSIMIR® for the Treatment of Post-Surgical Pain

    CUPERTINO, Calif., Oct. 2, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that the U.S. Food and Drug Administration (FDA) has notified the Company that its Class 2 NDA resubmission for POSIMIR®

  3. DURECT to Present at the 2019 Cantor Fitzgerald Global Health Care Conference

    CUPERTINO, Calif., Sept. 26, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that James E. Brown, Chief Executive Officer will be presenting at the Cantor Fitzgerald Global Health Care Conference,

  4. DURECT Announces Positive Data from its Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis

    CUPERTINO, Calif., Sept. 17, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that it has completed the Phase 2a clinical trial of its lead product candidate, DUR-928, in patients with alcoholic

  5. DURECT Earns $10 Million Milestone Payment for Further Development of a Long-Acting Injectable HIV Investigational Product Utilizing DURECT's SABER® Technology

    CUPERTINO, Calif., Sept. 9, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that further development of a long-acting injectable HIV investigational product utilizing DURECT's SABER® technology

  6. DURECT to Present at the 21st Annual Rodman and Renshaw Global Investment Conference Sponsored by H.C. Wainwright

    CUPERTINO, Calif., Sept. 4, 2019 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that James E. Brown, Chief Executive Officer will be presenting at the 21st Annual Global Rodman and Renshaw Investment